KPIs & Operating Metrics(New)
Balance Sheet
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInventory AverageInvested Capital

Astrazeneca (AZN) Assets Average (2016 - 2025)

Astrazeneca has reported Assets Average over the past 10 years, most recently at $109.1 billion for Q4 2025.

  • Quarterly results put Assets Average at $109.1 billion for Q4 2025, up 109.02% from a year ago — trailing twelve months through Dec 2025 was $109.1 billion (up 109.02% YoY), and the annual figure for FY2025 was $109.1 billion, up 109.02%.
  • Assets Average for Q4 2025 was $109.1 billion at Astrazeneca, up from $52.2 billion in the prior quarter.
  • Over the last five years, Assets Average for AZN hit a ceiling of $109.1 billion in Q4 2025 and a floor of $160.5 million in Q4 2021.
  • Median Assets Average over the past 5 years was $48.4 billion (2023), compared with a mean of $51.6 billion.
  • Biggest five-year swings in Assets Average: decreased 27.7% in 2021 and later skyrocketed 29989.41% in 2022.
  • Astrazeneca's Assets Average stood at $160.5 million in 2021, then skyrocketed by 29989.41% to $48.3 billion in 2022, then rose by 0.22% to $48.4 billion in 2023, then rose by 7.8% to $52.2 billion in 2024, then surged by 109.02% to $109.1 billion in 2025.
  • The last three reported values for Assets Average were $109.1 billion (Q4 2025), $52.2 billion (Q4 2024), and $48.4 billion (Q4 2023) per Business Quant data.